Cost-effectiveness models for chronic obstructive pulmonary disease: Cross-model comparison of hypothetical treatment scenarios

Value in Health

Volumn 17, Issue 5, 2014, Pages 525-536

  Hoogendoorn, Martine ^a   Feenstra, Talitha L ^b,c   Asukai, Yumi ^d   Borg, Sixten ^e,f   Hansen, Ryan N ^g   Jansson, Sven Arne ^h   Samyshkin, Yevgeniy ^d   Wacker, Margarethe ⁱ   Briggs, Andrew H ^j   Lloyd, Adam ^d   Sullivan, Sean D ^g   Rutten Van Mölken, Maureen P M H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d IQVIA   (United States)

^e SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g UNIVERSITY OF WASHINGTON   (United States)

^h OLIN Studies   (Sweden)

ⁱ INSTITUTE OF EPIDEMIOLOGY   (Germany)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

COPD; cost effectiveness; model; validation

Indexed keywords

INDACATEROL; ROFLUMILAST; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MODEL; DISEASE SEVERITY; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; LUNG FUNCTION; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STANDARDIZED MORTALITY RATIO; TREATMENT OUTCOME; UNCERTAINTY;

COPD; COST-EFFECTIVENESS; MODEL; VALIDATION;

COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MODELS, ECONOMIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SMOKING; UNCERTAINTY;

EID: 84906243763     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.03.1721     Document Type: Article

References (43)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www.goldcopd.com. [Accessed June 20, 2013].
2. L. Fuso, R.A. Incalzi, and R. Pistelli et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease Am J Med 98 1995 272 277
3. S.P. Patil, J.A. Krishnan, N. Lechtzin, and G.B. Diette In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease Arch Intern Med 163 2003 1180 1186
4. F. Andersson, S. Borg, and S.A. Jansson et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD) Respir Med 96 2002 700 708
5. J.B. Oostenbrink, and M.P. Rutten-van Molken Resource use and risk factors in high-cost exacerbations of COPD Respir Med 98 2004 883 891
6. J.F. O'Reilly, A.E. Williams, and L. Rice Health status impairment and costs associated with COPD exacerbation managed in hospital Int J Clin Pract 61 2007 1112 1120
7. A.S. Buist, M.A. McBurnie, and W.M. Vollmer et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study Lancet 370 2007 741 750
8. S.A. Jansson, F. Andersson, and S. Borg et al. Costs of COPD in Sweden according to disease severity Chest 122 2002 1994 2002
9. R. Lozano, M. Naghavi, and K. Foreman et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 9859 2012 2095 2128
10. C.J. Murray, T. Vos, and R. Lozano et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2197 2223
11. World Health Organization The Global Burden of Disease: 2004 Update 2008 World Health Organization Geneva, Switzerland
12. OECD. Health expenditure in relation to GDP. In: Health at a Glance: Europe. OECD Publishing, 2012. Available from: http://dx.doi.org/10.1787/ 9789264183896-53-en. [Accessed June 18, 2013].
13. D. Eddy, W. Hollingworth, and J.J. Caro et al. Model transparancy and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group - Part 4 Value Health 15 2012 843 850
14. D. Price, A. Gray, and R. Gale et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD Respir Med 150 2011 1635 1647
15. S. Borg, A. Ericsson, and J. Wedzicha et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease Value Health 7 2004 153 167
16. R.N. Hansen, X. Xu, and S.D. Sullivan A dynamic cohort model of chronic obstructive pulmonary disease and its treatments Value Health 15 2012 A54
17. M. Hoogendoorn, M.P. Rutten-van Molken, and R.T. Hoogenveen et al. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease Value Health 14 2011 1039 1047
18. M.P. Rutten-van Mölken, J.B. Oostenbrink, M. Miravitlles, and B.U. Monz Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain Eur J Health Econ 8 2007 123 135
19. Y. Samyshkin, R.W. Kotchie, and A.C. Mork et al. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom Eur J Health Econ 15 2014 69 82
20. P. Menn, R. Leidl, and R. Holle A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease Pharmacoeconomics 30 2012 825 840
21. R. Nielsen, A. Johannessen, and B. Benediktsdottir et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study Eur Respir J 34 2009 850 857
22. M. Spencer, A.H. Briggs, R.F. Grossman, and L. Rance Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease Pharmacoeconomics 23 2005 619 637
23. Pauwels RA, Buist AS, Calverley PM, et al., eds. Global Inititiative for Chronic Obstructive Lung Disease. Workshop Report: Global Strategy for the Diagnosis, Management and Prevention of COPD: Updated 2003. Bethesda, MD: National Heart, Lung, and Blood Institute/World Health Organization, 2003.
24. B. Lundback, A. Lindberg, and M. Lindstrom et al. Not 15 but 50% of smokers develop COPD? Report from the obstructive lung disease in northern Sweden Studies Respir Med 97 2003 115 122
25. K. Atsou, C. Chouaid, and G. Hejblum Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease PLoS One 6 2011 e24870
26. M. Hoogendoorn, M.P. Rutten-van Molken, and R.T. Hoogenveen et al. A dynamic population model of disease progression in COPD Eur Respir J 26 2005 223 233
27. H.J. Starkie, A.H. Briggs, M.G. Chambers, and P. Jones Predicting EQ-5D values using the SGRQ Value Health 14 2011 354 360
28. M. Hoogendoorn, T.L. Feenstra, R.T. Hoogenveen, and M.P. Rutten-van Molken Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD Thorax 65 2010 711 718
29. Hoogendoorn M, Rutten-van Mölken MPMH, Hoogenveen RT, et al., eds. Working Paper: Comparing the Cost-Effectiveness of a Wide Range of COPD Interventions using a Stochastic, Dynamic, Population Model for COPD. Rotterdam, The Netherlands: Erasmus University Rotterdam, Institute of Health, Policy and Management, 2010.
30. J.B. Oostenbrink, M.P. Rutten-van Mölken, B.U. Monz, and J.M. FitzGerald Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries Value Health 8 2005 32 46
31. Y. Samyshkin, M. Schlunegger, and S. Haefliger et al. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland Int J Chron Obstruct Pulmon Dis 8 2013 79 87
32. N. Hertel, R.W. Kotchie, and Y. Samyshkin et al. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis Int J Chron Obstruct Pulmon Dis 7 2012 183 199
33. A.H. Briggs, M.C. Weinstein, and E.A. Fenwick et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 6 Value Health 15 2012 835 842
34. Mount Hood 4 Modeling Group Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting Diabetes Care 30 2007 1638 1646
35. A.J. Palmer Mount Hood 5 Modeling Group Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood Challenge Meeting Value Health 16 2013 670 685
36. J. Hornberger Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood Challenge Meeting Value Health 16 2013 453 454
37. P.M. Calverley, J.A. Anderson, and B. Celli et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
38. D.P. Tashkin, B. Celli, and S. Senn et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
39. P. Lange, J.L. Marott, and J. Vestbo et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population Am J Respir Crit Care Med 186 2012 975 981
40. J.B. Soriano, I. Alfageme, and P. Almagro et al. Distribution and prognostic validity of the new global initiative for chronic obstructive lung disease grading classification Chest 143 2013 694 702
41. Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the GOLD 2011 COPD groups in the eclipse cohort. Eur Respir J 2013;42:636-646.
42. Y. Asukai, M. Baldwin, and T. Fonseca et al. Improving clinical reality in chronic obstructive pulmonary disease economic modelling: development and validation of a micro-simulation approach Pharmacoeconomics 31 2013 151 161
43. A. Briggs, D. Lomas, and M. Rutten-van Molken et al. Developing a new model of COPD: from conceptualisation to implementation to validation Value Health 16 2013 A234 A235